HOB BIOTECH(SH:688656) Xin Lang Cai Jing·2025-09-30 03:25Group 1 - The core viewpoint of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. has seen a stock price increase of 5.34%, reaching 162.43 CNY per share, with a total market capitalization of 10.311 billion CNY [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include sales from other products at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] Group 2 - From the perspective of fund holdings, one fund under Shenwan Hongyuan has Haobio as a significant investment, holding 56,100 shares, which constitutes 5.74% of the fund's net value [2] - The fund, Shenwan Hongyuan Medical Pioneer Stock A, has a current scale of 120 million CNY and has experienced a loss of 2.93% this year, ranking 4172 out of 4220 in its category [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 75 days, with the best and worst fund returns during his tenure being -30.26% and -31.14%, respectively [2]